Madrigal: Phase 3 Development of Resmetirom, a liver directed thyroid hormone receptor (THR)-β agonist for the treatment of patients with NASH and significant liver fibrosis - ILC 2021
View
Metabolism, Alcohol & Toxicity
2
Madrigal: Phase 3 Development of Resmetirom, a liver directed thyroid hormone receptor (THR)-β agonist for the treatment of patients with NASH and significant liver fibrosis - ILC 2021
View
General Hepatology
4
Gore & Associates: New clinical evidence demonstrates improved survival when selecting smaller TIPS and earlier TIPS - ILC 2021
View
General Hepatology
4
Gore & Associates: New clinical evidence demonstrates improved survival when selecting smaller TIPS and earlier TIPS - ILC 2021
View
General Hepatology
4
Gore & Associates: New clinical evidence demonstrates improved survival when selecting smaller TIPS and earlier TIPS - ILC 2021
View
General Hepatology
4
Gore & Associates: New clinical evidence demonstrates improved survival when selecting smaller TIPS and earlier TIPS - ILC 2021
